Journal of Neurology

, Volume 239, Issue 7, pp 401–403 | Cite as

Methionine in the treatment of nitrous-oxide-induced neuropathy and myeloneuropathy

  • Charles B. Stacy
  • Alessandro Di Rocco
  • Randall J. Gould
Original Communications

Summary

Two cases of severe myeloneuropathy and macrocytic anemia associated with a low serum level of vitamin B12 after prolonged exposure to nitrous oxide are reported. In both cases, the neurological manifestations worsened initially despite B12 supplementation, al though in one case the use of methionine seemed to arrest the progression of the disease and accelerate recovery. This offers further support for the biochemical hypothesis of methionine synthetase inhibition by nitrous oxide and reproduces in man previously reported animal studies with methionine. Methionine may be an important first-line therapy in the initial treatment of neuropathy and myeloneuropathy induced by nitrous oxide, and has a hypothetical role in the treatment of subacute combined degeneration of the cord.

Key words

Nitrous oxide Vitamin B12 Subacute combined degeneration Methionine Myeloneuropathy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Amess JAL, Burman JF, Rees GM, Nancekievill DG, Mollin DL (1978) Megaloblastic haemopoiesis in patients receiving nitrous oxide. Lancet II:339–342Google Scholar
  2. 2.
    Blanco G, Peters HA (1983) Myeloneuropathy and macrocytosis associated with nitrous oxide abuse. Arch Neurol 40:416–418Google Scholar
  3. 3.
    Deacon R, Lumb M, Perry J, Chanarin I, Minty B, Halsey MJ, Nunn JF (1978) Selective inactivation of vitamin B12 in rats by nitrous oxide. Lancet 11:1023–1024Google Scholar
  4. 4.
    Fairbanks VF, Elveback LR (1983) Tests for pernicious anemia: serum vitamin Bit assay. Mayo Clin Proc 58:135–137Google Scholar
  5. 5.
    Gillman MA (1987) Haematological changes caused by nitrous oxide. Br J Anaesth 59:143–146Google Scholar
  6. 6.
    Heyer EJ, Simpson DM, Bodis-Wollner I, Diamond SP (1986) Nitrous oxide: clinical and electrophysiologic investigation of neurologic complications. Neurology 36:1618–1622Google Scholar
  7. 7.
    Kolhouse JF, Kondo NC, Allen NC, Podell ER, Allen RH (1978) Cobalamin analogues are present in human plasma and can mask cobalamin deficiency because current radioisotope dilution assays are not specific for true cobalamin. N Engl J Med 299:785–792Google Scholar
  8. 8.
    Kondo H, et al (1981) Nitrous oxide has multiple deleterious effects on cobalamin metabolism and causes decreases in activity of both mammalian cobalamin-dependent enzymes in rats. J Clin Invest 67:1270–1283Google Scholar
  9. 9.
    Layzer RB (1978) Myeloneuropathy after prolonged exposure to nitrous oxide. Lancet 11:1227–1230Google Scholar
  10. 10.
    Layzer RB (1985) Neuromuscular manifestations of systemic disease. Davis, Philadelphia, pp 327–400Google Scholar
  11. 11.
    Layzer RB, Fishman RA, Schafer JA (1978) Neuropathy following abuse of nitrous oxide. Neurology 28:504–506Google Scholar
  12. 12.
    Lindenbaum J, et al (1988) Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 318:1720–1728Google Scholar
  13. 13.
    Lindenbaum J, Savage DG, Stabler SP, Allen RH (1990) Diagnosis of cobalamin deficiency. II. Relative sensitivities of serum cobalamin, methylmalonic acid and total homocysteine concentrations. Am J Hematol 34:99–107Google Scholar
  14. 14.
    Lombardini JB, Coulter AW, Talay P (1970) Analogues of methionine as substrates and inhibitors of the methionine adenosyltransferase reaction. Deductions concerning the conformation of methionine. Mol Pharmacol 6:481–499Google Scholar
  15. 15.
    McCann SR, Weir DJ, Dinn JJ, Wilson P, Scott J (1979) Neurological damage induced by nitrous oxide in the monkey in absence of any detectable haematological change. Br J Haematol 43:496Google Scholar
  16. 16.
    Nunn JF (1987) Clinical aspects of the interaction between nitrous oxide and vitamin B12. Br J Anaesth 59:3–13Google Scholar
  17. 17.
    Pulsson GW (1979) “Recreational” misuse of nitrous oxide. J Am Dent Assoc 98:410–411Google Scholar
  18. 18.
    Sahenk Z, Mendell JR, Couri D, Nachtman J (1978) Polyneuropathy from inhalation of N20 cartridges through a whippedcream dispenser. Neurology 28:485–487Google Scholar
  19. 19.
    Schilling RF (1986) Is nitrous oxide a dangerous anesthetic for vitamin B12-deficient subjects? JAMA 255:1605–1606Google Scholar
  20. 20.
    Scott JM, Weir DJ (1981) The methyl folate trap. Lancet II:337–340Google Scholar
  21. 21.
    Scott JM, Dinn JJ, Wilson P, Weir DG (1981) Pathogenesis of subacute combined degeneration: a result of methyl group deficiency. Lancet II:334–337Google Scholar
  22. 22.
    Shimizu T, Nishimura Y, Fujishima Y, Miyajima H, Honda N (1989) Subacute myeloneuropathy after abuse of nitrous oxide: an electron microscopic study on the peripheral nerve (in Japanese). Rinsho Shinkergaku 29:129–135Google Scholar
  23. 23.
    Vina JR, Davis DW, Hawkins RA (1986) The influence of nitrous oxide on methionine, S-adenosylmethionine, and other amino acids. Anesthesiology 64:490–495Google Scholar
  24. 24.
    Williams SR (1989) Nutrition and diet therapy, 6th edn. Times Mirror, Mosby, St Louis Toronto Boston, pp 874–875Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Charles B. Stacy
    • 1
  • Alessandro Di Rocco
    • 1
  • Randall J. Gould
    • 2
  1. 1.Department of NeurologyThe Mount Sinai Medical CenterNew YorkUSA
  2. 2.Department of MedicineBeth Israel Medical CenterNew YorkUSA

Personalised recommendations